Page last updated: 2024-10-27

flecainide and Idiopathic Parkinson Disease

flecainide has been researched along with Idiopathic Parkinson Disease in 1 studies

Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).

Research Excerpts

ExcerptRelevanceReference
"Excessive daytime sleepiness (EDS) is a frequent and disabling symptom of Parkinson's disease (PD) without approved treatment."3.11THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial. ( Azulay, JP; Bosse, B; Corvol, JC; Dauvilliers, Y; Defebvre, L; Klostermann, F; Kovacs, N; MaltĂȘte, D; Ondo, WG; Pahwa, R; Rascol, O; Rein, W; Thobois, S; Valis, M; Videnovic, A, 2022)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Corvol, JC1
Azulay, JP1
Bosse, B1
Dauvilliers, Y1
Defebvre, L1
Klostermann, F1
Kovacs, N1
MaltĂȘte, D1
Ondo, WG1
Pahwa, R1
Rein, W1
Thobois, S1
Valis, M1
Videnovic, A1
Rascol, O1

Trials

1 trial available for flecainide and Idiopathic Parkinson Disease

ArticleYear
THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial.
    Movement disorders : official journal of the Movement Disorder Society, 2022, Volume: 37, Issue:2

    Topics: Disorders of Excessive Somnolence; Double-Blind Method; Drug Combinations; Flecainide; Humans; Modaf

2022